Chimeric Therapeutics Ltd (ASX:CHM) Share Price

Company Profile

Business description
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
Contact
62 Lygon Street
Level 3, Carlton
MelbourneVIC3053
AUS
T: +61 398245254
https://www.chimerictherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees

Recommended

Our coverage remains overvalued.

Jon Mills, CFA | 14 January 2026

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.

William Kerwin, CFA | 12 January 2026

The shares are overvalued as investors are overly excited about defence and gold exposure.

Esther Holloway | 12 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,151.80	24.70	0.27%
CAC 40	8,358.42	11.22	0.13%
DAX 40	25,319.26	101.40	-0.40%
Dow JONES (US)	49,191.99	398.21	-0.80%
FTSE 100	10,167.30	29.95	0.30%
HKSE	26,999.81	391.33	1.47%
NASDAQ	23,709.87	24.03	-0.10%
Nikkei 225	54,341.23	2,401.34	4.62%
NZX 50 Index	13,757.71	101.66	0.74%
S&P 500	6,963.74	13.53	-0.19%
S&P/ASX 200	8,820.60	29.30	0.33%
SSE Composite Index	4,126.09	12.67	-0.31%